ABT-450

Known as: ABT 450, ABT450 
 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Macrocyclic Compounds

Narrower (1)

paritaprevir

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised…
BACKGROUND Hepatitis C virus (HCV) genotype 4 accounts for about 13% of global HCV infections. Because interferon-containing… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
BACKGROUND The interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r) and the NS5A inhibitor… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2014
Highly Cited
2014
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.
BACKGROUND Interferon-containing regimens for the treatment of hepatitis C virus (HCV) infection are associated with increased… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2014
Highly Cited
2014
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
BACKGROUND In this phase 3 trial we evaluated the efficacy and safety of the interferon-free combination of ABT-450 with… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
BACKGROUND The interferon-free regimen of ABT-450 with ritonavir (ABT-450/r), ombitasvir, and dasabuvir with or without ribavirin… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.
BACKGROUND & AIMS The interferon-free regimen of ABT-450 (a protease inhibitor), ritonavir, ombitasvir (an NS5A inhibitor… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
An interferon-free antiviral regimen for HCV after liver transplantation.
BACKGROUND Hepatitis C virus (HCV) infection is the leading indication for liver transplantation worldwide, and interferon… (More)
Is this relevant?
Review
2014
Review
2014
New antiviral agents for the treatment of hepatitis C: ABT-450.
INTRODUCTION Hepatitis C virus (HCV) therapy continues to evolve rapidly. ABT-450 is a novel potent inhibitor of the non… (More)
Is this relevant?
Highly Cited
2014
Highly Cited
2014
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.
BACKGROUND An interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r), the nonnucleoside… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Exploratory study of oral combination antiviral therapy for hepatitis C.
BACKGROUND There is a need for interferon-free treatment regimens for hepatitis C virus (HCV) infection. The goal of this study… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?